Patents Assigned to Transgene S.A.
-
Patent number: 10857226Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: GrantFiled: September 17, 2018Date of Patent: December 8, 2020Assignee: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
-
Publication number: 20200197457Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: ApplicationFiled: December 23, 2019Publication date: June 25, 2020Applicant: Transgene S.A.Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Patent number: 10662414Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: GrantFiled: January 25, 2019Date of Patent: May 26, 2020Assignee: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Patent number: 10555981Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: GrantFiled: July 16, 2015Date of Patent: February 11, 2020Assignee: Transgene S.A.Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Patent number: 10517943Abstract: The present invention relates to liquid formulations of poxvirus, in particular vaccinia virus, stable during storage. Such stable liquid formulations comprise a) a poxvirus, preferably a vaccinia virus, b) a pharmaceutically acceptable buffer, c) a monovalent salt, d) a pharmaceutically acceptable disaccharide or sugar alcohol, and e) a pharmaceutically acceptable chelating agent, wherein the pH of the formulation is comprised between 6.5 and 8.5.Type: GrantFiled: December 1, 2015Date of Patent: December 31, 2019Assignee: Transgene S.A.Inventor: Mélina Chasle
-
Publication number: 20190144840Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: ApplicationFiled: January 25, 2019Publication date: May 16, 2019Applicant: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Publication number: 20190070285Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: ApplicationFiled: September 17, 2018Publication date: March 7, 2019Applicant: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
-
Patent number: 10190105Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: GrantFiled: December 5, 2016Date of Patent: January 29, 2019Assignee: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Patent number: 10111947Abstract: The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected in the group of polyvinylpyrrolidone and derivatives thereof, (iii) at least one sugar, (iv) at least two different amino acids, (v) at least two pharmaceutical acceptable salts, wherein at least one of said salts is a phosphate salt and, optionally (vi) a pharmaceutical acceptable buffer. Such a formulation is particularly suitable for freeze-drying. The present invention also relates to the corresponding dry product, as well as its preparation process. The present invention also relates to a reconstituted material comprising said dry product, which can be administered to a patient in need thereof. Such formulation and reconstituted material are useful as vaccines, preferably for the treatment and/or the prevention of cancers, infectious diseases and/or autoimmune disorders.Type: GrantFiled: October 2, 2013Date of Patent: October 30, 2018Assignee: Transgene S.A.Inventors: Claude Sene, Mélina Chasle
-
Patent number: 10076570Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: GrantFiled: March 17, 2012Date of Patent: September 18, 2018Assignee: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
-
Patent number: 9982055Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.Type: GrantFiled: July 19, 2016Date of Patent: May 29, 2018Assignee: TRANSGENE S.A.Inventors: Hélène Haegel, Christine Thioudellet, Michel Geist, Benoit Grellier, Jean-Baptiste Marchand
-
Patent number: 9884080Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.Type: GrantFiled: February 27, 2013Date of Patent: February 6, 2018Assignee: Transgene S.A.Inventors: Philippe Erbs, Johann Foloppe
-
Patent number: 9687515Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.Type: GrantFiled: April 10, 2014Date of Patent: June 27, 2017Assignee: Transgene S.A.Inventors: Philippe Erbs, Johann Foloppe
-
Publication number: 20170157188Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: ApplicationFiled: July 16, 2015Publication date: June 8, 2017Applicant: Transgene S.A.Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Publication number: 20170145392Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: ApplicationFiled: December 5, 2016Publication date: May 25, 2017Applicant: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Publication number: 20170072047Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: ApplicationFiled: July 6, 2016Publication date: March 16, 2017Applicant: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt
-
Patent number: 9512412Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: GrantFiled: July 12, 2012Date of Patent: December 6, 2016Assignee: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Patent number: 9428584Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.Type: GrantFiled: May 17, 2013Date of Patent: August 30, 2016Assignee: Transgene S.A.Inventors: Hèléne Haegel, Christine Thioudellet, Michel Geist, Benoît Grellier, Jean-Baptiste Marchand
-
Patent number: 9393299Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: GrantFiled: August 6, 2010Date of Patent: July 19, 2016Assignee: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt
-
Patent number: 9295702Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: GrantFiled: December 23, 2014Date of Patent: March 29, 2016Assignee: Transgene S.A.Inventors: Daniel Malarme, Yves Cordier, Claude Sene